CoronaVac

BIOLOGICAL16 trials

Conditions

AIDSAdverse Reaction to VaccineCOVID-19COVID-19 PandemicCOVID-19 SARS-CoV-2 InfectionCOVID-19 VaccinationCOVID19 VaccineChronic Liver Disease

Early Phase 1

Exploratory Clinical Study to Evaluation of the Safety and Immunogenicity of Bivalent Vaccine V-01D-351

NCT05583357

Livzon Pharmaceutical Group Inc.COVID-19 Pandemic

Start: 2022-08-15End: 2023-08-10Updated: 2022-10-19

The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001

NCT05928455

Guangzhou Patronus Biotech Co., Ltd.COVID-19, Vaccine Reaction

Start: 2022-05-14End: 2023-06-30Updated: 2023-07-03

Phase 2

Covid-19 Vaccination in Adolescents and Children

NCT04800133

The University of Hong KongCovid19

Start: 2021-05-08End: 2025-03-31Updated: 2024-01-16

Booster Vaccination Against COVID-19

CompletedNCT04979949

Health Institutes of TurkeyCOVID-19, Sars-CoV-2 Infection

Start: 2021-07-12End: 2022-06-06Updated: 2023-11-29

Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy Adolescent

CompletedNCT05230940

Health Institutes of TurkeyCOVID-19, Sars-CoV-2 Infection

Start: 2022-02-18End: 2024-02-08Updated: 2024-05-28

Phase 3

Clinical Trial For SARS-CoV-2 Vaccine (COVID-19)

CompletedNCT04582344

Health Institutes of TurkeyCOVID-19

Start: 2020-09-14End: 2022-07-27Updated: 2024-05-24

Efficacy, Immunogenicity, and Safety of the Inactivated COVID-19 Vaccine (TURKOVAC) Versus the CoronaVac Vaccine

CompletedNCT04942405

Health Institutes of TurkeyCovid19

Start: 2021-06-21End: 2024-02-01Updated: 2024-02-29

Phase 3 Booster Vaccination Against COVID-19

CompletedNCT05077176

Health Institutes of TurkeyCOVID-19, Sars-CoV-2 Infection

Start: 2021-10-08End: 2024-02-05Updated: 2024-02-29

A Phase III Clinical Trial to Evaluate the Efficacy and Safety of SCTV01E in Healthy People

NCT05683561

Sinocelltech Ltd.COVID-19 SARS-CoV-2 Infection

Start: 2023-01-25End: 2024-08-25Target: 6000Updated: 2023-01-13

Phase 4

COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS

CompletedNCT04754698

University of Sao Paulo General HospitalAIDS, COVID-19, HIV Infections +3

Start: 2021-02-09End: 2024-03-22Updated: 2024-03-26

Antibody Response to COVID-19 Vaccines in Liver Disease Patients

CompletedNCT04775069

Humanity & Health Medical Group LimitedChronic Liver Disease

Start: 2021-05-21End: 2023-09-30Updated: 2023-10-04

Evaluate the Impact, Safety, Tolerability and Immunogenicity of the Coronavac Vaccine in Kidney Transplant Recipients

NCT04801667

Hospital do Rim e HipertensãoCoronavirus Infection, SARS-CoV Infection, Vaccine Adverse Reaction

Start: 2021-03-20End: 2023-03-01Updated: 2022-03-18

Randomized Trial of COVID-19 Booster Vaccinations (Cobovax Study)

CompletedNCT05057169

The University of Hong KongCOVID-19 Vaccination

Start: 2021-11-18End: 2025-12-31Updated: 2026-05-15

Heterologous Boost Immunization with Ad5-nCoV After Three-dose Priming with an Inactivated SARS-CoV-2 Vaccine

CompletedNCT05303584

Jiangsu Province Centers for Disease Control and PreventionCOVID-19

Start: 2022-04-23End: 2023-05-31Updated: 2025-02-21

Immunogenicity and safety of CoronaVac vaccine (Covid-19 vaccine) in Thai people with underlying disease

Active, not recruitingTCTR20220720001

Chulabhorn Royal AcademyDiabetes mellitus Cirrhosis solid cancer Hematologic malignancy chronic kidney disease rheumatological disease cardiovascular disease CoronaVac vaccine immunogenicity covid-19 vaccine

Start: 2021-06-08Target: 420Updated: 2026-08-03

Unknown Phase

COVID-19 Vaccines Safety Tracking (CoVaST)

RecruitingNCT04834869

Masaryk UniversityAdverse Reaction to Vaccine, COVID19 Vaccine

Start: 2021-04-01End: 2026-12-31Target: 30000Updated: 2022-04-06

2024-08-275 citations

Superior antibody and membrane protein-specific T-cell responses to CoronaVac by intradermal versus intramuscular routes in adolescents.

2023-12-122 citations

Comparative antibody and cell-mediated immune responses, reactogenicity, and efficacy of homologous and heterologous boosting with CoronaVac and BNT162b2 (Cobovax): an open-label, randomised trial.

2023-08-0416 citations

Long-Term Results of Immunogenicity of Booster Vaccination against SARS-CoV-2 (Hybrid COV-RAPEL TR Study) in Turkiye: A Double-Blind, Randomized, Controlled, Multicenter Phase 2 Clinical Study

Vaccines2023-07-121 citations

Post-acute COVID-19 in three doses vaccinated autoimmune rheumatic diseases patients: frequency and pattern of this condition

Advances in Rheumatology2023-06-08

Environmental Impact Assessment for the Use of an Orally Aerosolized Adenovirus Type-5 Vector-Based COVID-19 Vaccine in Randomized Clinical Trials

The Journal of Infectious Diseases2023-05-181 citations

Safety and immunogenicity of aerosolised Ad5-nCoV, intramuscular Ad5-nCoV, or inactivated COVID-19 vaccine CoronaVac given as the second booster following three doses of CoronaVac: a multicentre, open-label, phase 4, randomised trial.

2023-03-0742 citations

Immunogenicity against wild-type and Omicron SARS-CoV-2 after a third dose of inactivated COVID-19 vaccine in healthy adolescents

Frontiers in Immunology2023-03-069 citations

The Bivalent COVID-19 Booster Immunization after Three Doses of Inactivated Vaccine Augments the Neutralizing Antibody Response against Circulating Omicron Sublineages

Journal of Clinical Medicine2022-12-2412 citations

Antibody and T cell responses against wild-type and Omicron SARS-CoV-2 after third-dose BNT162b2 in adolescents.

2022-12-1410 citations

Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose.

2022-11-291 citations

Safety and immunogenicity of an inactivated whole virion SARS-CoV-2 vaccine, TURKOVAC, in healthy adults: Interim results from randomised, double-blind, placebo-controlled phase 1 and 2 trials.

2022-11-2214 citations

Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial

Vaccines2022-11-0416 citations

Safety and immunogenicity of inactive vaccines as booster doses for COVID-19 in Türkiye: A randomized trial

Human Vaccines & Immunotherapeutics2022-10-3116 citations

Immunogenicity decay and case incidence six months post Sinovac-CoronaVac vaccine in autoimmune rheumatic diseases patients

Nature Communications2022-10-0310 citations

Safety and immunogenicity of 3 doses of BNT162b2 and CoronaVac in children and adults with inborn errors of immunity

Frontiers in Immunology2022-09-2017 citations

Interaction of TNFi and conventional synthetic DMARD in SARS-CoV-2 vaccine response in axial spondyloarthritis and psoriatic arthritis.

2022-09-207 citations

Physical activity and antibody persistence 6 months after the second dose of <scp>CoronaVac</scp> in immunocompromised patients

Scandinavian Journal of Medicine and Science in Sports2022-07-185 citations

Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents

Nature Communications2022-06-2866 citations

Strong response after fourth dose of mRNA COVID-19 vaccine in autoimmune rheumatic diseases patients with poor response to inactivated vaccine

Lara D. Veeken2022-05-2618 citations

18 more papers not shown

CoronaVac

Sponsors

Conditions

Early Phase 1

Phase 2

Phase 3

Phase 4

Unknown Phase

Related Papers